Premium
Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma
Author(s) -
Wilcox Pearce G,
Ahmad Dildar,
Darke Andrew C,
Parsons James,
Carruthers S George
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.5
Subject(s) - metoprolol , medicine , asthma , bronchoconstriction , crossover study , anesthesia , respiratory system , clinical pharmacology , dosing , cumulative dose , cardiology , pharmacology , alternative medicine , pathology , placebo
The effects on standing heart rate and respiratory function of two relatively selective β 1 ‐adrenoceptor antagonists, metoprolol and bevantolol, were compared in a double‐blind, randomized, crossover study of 16 patients with asthma. After control observations on 2 separate days, the patients received approximately equivalent cardiac β‐adrenoceptor antagonist doses of metoprolol, 12.5, 25, 50, and 100 mg, and bevantolol, 18.75, 37.5, 75 and 150 mg, at intervals of 2 hours. Dosing was stopped if symptoms warranted or if there was a fall of ≥20% in the forced expiratory volume in 1 second. In general, the cumulative dosing regimen proved a safe and effective means of assessing bronchial responsiveness to these β‐blockers in asthma, but one patient had to be dropped from the study because of severe bronchoconstriction after the first dose. Of the 15 patients studied who were taking both drugs, seven patients were withdrawn prematurely. In these seven patients, the average maximum tolerated cumulative doses were 45.5 mg bevantolol and 26.8 mg metoprolol, doses that are much lower than those usually required for therapeutic activity. The respiratory response to either drug could not be predicted. Clinical Pharmacology and Therapeutics (1986) 39, 29–34; doi: 10.1038/clpt.1986.5